Sees FY25 gross margin between 61% – 63%; Operational cash flow positive for the full year 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRMD:
- Buy Recommendation for REPRO-MED Systems: Strong Fundamentals and Growth Opportunities Drive Potential
- KRMD Earnings this Week: How Will it Perform?
- Koru Medical downgraded to Neutral from Overweight at Piper Sandler
- Koru announces pact for next-gen subcutaneous immunoglobulin infusion system
- Koru Medical announces Phase 3 trial collaboration for new drug indication